relapsed Small Lymphocytic Lymphoma (DBCOND0023539)

Identifiers

Synonyms

Small Lymphocytic Lymphoma, Relapsed / Relapsed small lymphocytic lymphoma

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Duvelisib	An inhibitor of phosphatidylinositol 3-kinase delta and gamma used to treat relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.	Cytochrome P450 3A4enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoformtarget Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformtarget
Idelalisib	An antineoplastic kinase inhibitor used to treat chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL).	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformtarget Broad substrate specificity ATP-binding cassette transporter ABCG2transporter ATP-dependent translocase ABCB1transporter Aldehyde oxidaseenzyme Cytochrome P450 2C8enzyme Cytochrome P450 2C19enzyme Cytochrome P450 2B6enzyme Cytochrome P450 3A4enzyme Solute carrier organic anion transporter family member 1B1transporter Solute carrier organic anion transporter family member 1B3transporter Cytochrome P450 3A5enzyme Cytochrome P450 3A43enzyme Cytochrome P450 3A7enzyme UDP-glucuronosyltransferase 1A4enzyme
Lisocabtagene maraleucel	A CAR T-cell therapy for treatment resistant or more severe B-cell lymphomas.	B-lymphocyte antigen CD19target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05645744	Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.	MB-102 CD123 CAR	Not Available	Not Available	terminated
NCT05360238	Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL	No drug interventions	treatment	1 / 2	terminated
NCT05828589	A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies	No drug interventions	treatment	1	recruiting
NCT04191187	Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies	Fludarabine Melphalan	treatment	2	active_not_recruiting
NCT03639324	Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL	No drug interventions	treatment	1	withdrawn
NCT02722668	UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep	Cyclophosphamide Fludarabine Mycophenolate mofetil Sirolimus	treatment	2	active_not_recruiting